Annual report pursuant to Section 13 and 15(d)

Collaboration and Research Arrangements - Additional Information (Details)

v3.20.4
Collaboration and Research Arrangements - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Dec. 17, 2019
Jan. 08, 2018
Nov. 30, 2019
Jan. 31, 2018
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Accounts receivable         $ 7,000       $ 20,000,000       $ 7,000 $ 20,000,000  
Contract asset balance         2,324,000       158,000       2,324,000 158,000  
Revenue recognized         5,698,000 $ 3,828,000 $ 3,188,000 $ 2,379,000 508,000 $ 558,000 $ 462,000 $ 454,000 15,093,000 1,982,000 $ 2,050,000
Deferred revenue         22,086,000       28,378,000       22,086,000 28,378,000  
Deferred revenue, net of current portion         9,877,000       22,639,000       9,877,000 22,639,000  
Global Blood Therapeutics                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Revenue recognized                         11,700,000    
Deferred revenue         16,721,000       20,000,000       16,721,000 20,000,000  
Global Blood Therapeutics | Collaboration Agreement                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Initial period of research term 3 years                            
Additional extension period for research term upon mutual agreement 1 year                            
Upfront payment receivable $ 20,000,000.0                            
Reimbursements receivable of full-time employee and out-of-pocket costs and expenses $ 40,000,000.0                            
Agreement termination, prior written notice if notice delivered during the research term 9 months                            
Agreement termination, prior written notice if notice delivered after the expiration or termination of the research term 90 days                            
Total transaction price $ 60,000,000.0                       60,000,000.0    
Upfront non-refundable and non-creditable payment 20,000,000.0                            
Reimbursable costs $ 40,000,000.0                            
Change in total transaction price                         0    
Accounts receivable         0       20,000,000.0       0 20,000,000.0  
Contract asset balance         2,300,000       0       2,300,000 0  
Revenue recognized                         11,700,000 0  
Deferred revenue         16,700,000       20,000,000.0       16,700,000 20,000,000.0  
Deferred revenue, short-term         8,400,000       4,500,000       8,400,000 4,500,000  
Deferred revenue, net of current portion         8,300,000       15,500,000       8,300,000 15,500,000  
Global Blood Therapeutics | Collaboration Agreement | Maximum                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Period of extension of initial research term 2 years                            
Receivable from option exercise, development, regulatory, commercialization and sales-based milestones per product candidate and product resulting $ 315,000,000.0                            
Incyte                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Revenue recognized                         3,400,000 2,000,000.0 $ 2,100,000
Deferred revenue         5,365,000       $ 8,378,000       5,365,000 $ 8,378,000  
Deferred revenue, short-term         3,800,000               3,800,000    
Deferred revenue, net of current portion         $ 1,600,000               $ 1,600,000    
Incyte | Stock Purchase Agreement                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Aggregate purchase price       $ 10,000,000.0                      
Shares issued       793,021                      
Share price (in dollars per share)       $ 12.61                      
Premium to volume-weighted sale price of shares (as a percent)       30.00%                      
Trading days within which the purchase price represents a thirty percent (30%) premium to the volume-weighted sale price of the shares       15 days                      
Incyte | Collaboration Agreement                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Total transaction price   $ 12,300,000 $ 12,800,000                        
Upfront non-refundable and non-creditable payment     2,500,000                        
Up-front consideration       $ 10,000,000.0                      
Up-front consideration, cash       2,500,000                      
Up-front consideration, pre-paid research funding       $ 7,500,000                      
Prepaid research amount     7,500,000                        
Premium paid on equity investment     2,300,000                        
Collaboration agreement additional consideration incurred     $ 500,000